Perrigo Company plc (NYSE:PRGO) shares traded 3.14% higher at $30.55 on Wall Street last session.
In accordance with the data, 5 analysts cover Perrigo Company plc (NYSE:PRGO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $49.00 and a low of $37.00, we find $48.00. Given the previous closing price of $29.62, this indicates a potential upside of 62.05 percent. PRGO stock price is now 2.59% away from the 50-day moving average and -9.76% away from the 200-day moving average. The market capitalization of the company currently stands at $4.14B.
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $44.67 as their price target over the next twelve months.
With the price target of $37, Piper Sandler recently initiated with Overweight rating for Perrigo Company plc (NYSE: PRGO).
In other news, Willis Robert, EVP & CHRO bought 5,550 shares of the company’s stock on Nov 24. The stock was bought for $172,106 at an average price of $31.01. Upon completion of the transaction, the EVP & CHRO now directly owns 19,105 shares in the company, valued at $0.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16, EVP & Chief Scientific Officer Ives Alison bought 2,040 shares of the business’s stock. A total of $59,854 was incurred on buying the stock at an average price of $29.34. This leaves the insider owning 10,380 shares of the company worth $0.32 million. Insiders disposed of 340,432 shares of company stock worth roughly $10.4 million over the past 1 year. A total of 0.45% of the company’s stock is owned by insiders.
Perrigo Company plc (NYSE: PRGO) opened at $29.63 on Thursday. During the past 12 months, Perrigo Company plc has had a low of $26.81 and a high of $40.28. As of last week, the company has a debt-to-equity ratio of 0.90, a current ratio of 2.74, and a quick ratio of 1.60. According to the stock market information, the enterprise value for the company is $7.68B, which is based on a 9546.87 price-to-earnings ratio, a 954.69 price-to-earnings-growth ratio, and a beta of 0.73. The fifty day moving average price for PRGO is $29.76 and a two-hundred day moving average price translates $33.82 for the stock.
The latest earnings results from Perrigo Company plc (NYSE: PRGO) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.64, beating analysts’ expectations of $0.62 by 0.02. This compares to $0.02 EPS in the same period last year. The net profit margin was 0.02% and return on equity was 0.22% for PRGO. The company reported revenue of $1.12 billion for the quarter, compared to $1.1 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.15 percent. For the current quarter, analysts expect PRGO to generate $1.18B in revenue.
Perrigo Company plc(PRGO) Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women’s health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt’s Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
